The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Retinal Vascular Caliber as a Biomarker for Diabetes Microvascular Complications
Open accessAbstract
Globally, the number of people with diabetes is expected to reach 552 million in 2030 (1). Both the macrovascular (coronary artery disease, peripheral artery disease, and stroke) and microvascular (retinopathy, nephropathy, and neuropathy) complications of diabetes are major causes of morbidity and mortality (2). In theory, the long preclinical phase should provide a window to apply interventions that preempt progression to clinical disease, but to date no strategy achieves this aim for diabetes complications. Intensive control of hyperglycemia and blood pressure implemented with the imperfect means available today delays the appearance and reduces the severity of most complications, but does not prevent their development (3). Drugs such as fenofibrate have reduced the risk of diabetic retinopathy (DR) progression in type 2 diabetic patients, and inhibitors of the renin-angiotensin system (e.g., enalapril, losartan) have reduced the risk of progression in type 1 diabetic patients, but have not reduced the risk of DR incidence. Thus, new approaches are required to derive further benefit from current interventions at an earlier stage of diabetes and to support the development of new interventions. One such approach is to identify biomarkers that will enable systematic patient surveillance and the identification of high-risk patients and also surrogate end points that will accelerate the discovery of new interventions. The retinal vessels are early and prevalent targets of diabetic damage. They can be seen, measured, and tested by noninvasive means (4). Hence, investigators have attempted over the decades to identify early changes in the retinal vessels in diabetes and determine whether they could inform about the development of retinopathy and other complications. New measuring techniques have steadily come along, and others are in development. It seems timely to assess which concepts have emerged and which needs must be met toward fulfilling the expectation that retinal vessels may be able …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
Assessing the incremental value of diagnostic and prognostic markers: a review and illustration
Steyerberg, E. W., Pencina, M. J., Lingsma, H. F., Kattan, M. W., Vickers, A. J., & Van Calster, B. (2012) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02562.x · Cited by 219
Cited by
The progress in understanding and treatment of diabetic retinopathy
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A., Gardiner, T. A., Lyons, T. J., Hammes, H.-P., Simó, R., et al. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.08.001 · Cited by 1,164
Biomarkers in Diabetic Retinopathy
Jenkins, A. J., Joglekar, M. V., Hardikar, A. A., Keech, A. C., O'Neal, D. N., & Januszewski, A. S. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.159 · Cited by 296
Adaptive optics imaging of the human retina
Burns, S. A., Elsner, A. E., Sapoznik, K. A., Warner, R. L., & Gast, T. J. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.08.002 · Cited by 263
Chang, L. Y. L., Lowe, J., Ardiles, A., Lim, J., Grey, A. C., Robertson, K., Danesh‐Meyer, H., Palacios, A. G., & Acosta, M. L. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.06.004 · Cited by 106
Suzumura, A., Terao, R., & Kaneko, H. (2020) · Antioxidants · doi:10.3390/antiox9100920 · Cited by 44
Metadata
- Authors
- Ikram, M. K., Cheung, C. Y., Lorenzi, M., Klein, R., Jones, T. L. Z., Wong, T. Y., & for the NIH/JDRF Workshop on Retinal Biomarker for Diabetes Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-02-13
- Volume
- 36
- Issue
- 3
- Pages
- 750-759
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2127868552
- Cited by
- 180
- References
- 2
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.